Sexual Assault: PEP is an Urgent Health Need

Publish Date: 
Wednesday, October 17, 2018

When a patient presents to your emergency department, urgent care or clinic with a chief complaint of sexual assault within the last 24 hours, the challenge is recognizing that, along with safety and criminal justice concerns, this patient has emergent health needs. One of the most urgent of these is that the patient may have been exposed to HIV.  Non-occupational post-exposure prophylaxis (nPEP) needs to be initiated as soon as possible after known or potential HIV exposure, but throughout the country, there are barriers to this treatment. 

Doravirine--New NNRTI Approved by FDA

Publish Date: 
Wednesday, October 10, 2018

The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons

Short Bites: HIV in the Southeast United States

Publish Date: 
Thursday, October 4, 2018

Southern states today account for an estimated 44 percent of all people living with an HIV diagnosis in the U.S.,[1] despite having only about one-third (37%) of the overall U.S. population. Diagnosis rates for people in the South are higher than for Americans overall. Eight of the 10 states with the highest rates of new HIV diagnoses are in the South, as are the 10 metropolitan statistical areas (MSAs) with the highest rates.[1] The South faces internal disparities based on geography.

Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy

Publish Date: 
Tuesday, September 25, 2018

Although DTG currently is not a desirable medication for women to take pre-conception (see Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects), findings from the DolPHIN study suggest that it may be a very useful agent for women who start ART during late pregnancy.

TargetHIV: New Name, New Look

Publish Date: 
Wednesday, September 12, 2018

It's easier than ever to stay on target. The Health Resources and Services Administration's (HRSA) Ryan White HIV/AIDS Program (RWHAP) technical assistance (TA) and training website has undergone a major update to make it easier for users to access tools and materials for the RWHAP. The website, formerly called TARGET Center, is now named TargetHIV. Beyond the name change, there have been multiple revisions and updates, including a new look, easier navigation, and decluttering of the content.

Dolutegravir + 3TC in Initial Therapy

Susa Coffey's picture
Publish Date: 
Tuesday, August 21, 2018

As we have commented in the past, initial ARV regimens consisting of 2 drugs tend to perform poorly in comparison with currently recommended 3-drug regimens. Yet, given toxicity concerns about some ARVs (particularly about tenofovir DF and abacavir) and cost concerns about 3-drug regimens, the search for a potent and tolerable 2-drug regimen has continued. At the recent International AIDS Conference in late July, data were presented

Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study

Susa Coffey's picture
Publish Date: 
Monday, August 20, 2018

The U.S. Food and Drug Administration has given approval to a coformulation of darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg, to be marketed under the brand name Symtuza. DRV/COBI/FTC/TAF constitutes a complete regimen for patients with susceptible HIV, and is the first protease inhibitor-containing single-tablet regimen (STR). The approval is specifically for initial HIV treatment and for


Subscribe to Sharespot RSS feed